Steen Lisby

7.7k total citations
86 papers, 2.8k citations indexed

About

Steen Lisby is a scholar working on Pathology and Forensic Medicine, Genetics and Immunology. According to data from OpenAlex, Steen Lisby has authored 86 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 29 papers in Genetics and 29 papers in Immunology. Recurrent topics in Steen Lisby's work include Chronic Lymphocytic Leukemia Research (29 papers), Lymphoma Diagnosis and Treatment (28 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Steen Lisby is often cited by papers focused on Chronic Lymphocytic Leukemia Research (29 papers), Lymphoma Diagnosis and Treatment (28 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Steen Lisby collaborates with scholars based in United States, Denmark and United Kingdom. Steen Lisby's co-authors include Torkil Menné, O Baadsgaard, Gunhild L. Vejlsgaard, Christian S. Jensen, Per Soelberg Sørensen, Ira Gupta, Robert Gniadecki, Kevin D. Cooper, Ole Baadsgaard and Elisabeth Ralfkiær and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Steen Lisby

84 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steen Lisby United States	31	1.0k	910	808	695	617	86	2.8k
Astrid Jüngel Switzerland	37	1.1k 1.1×	1.1k 1.2×	601 0.7×	453 0.7×	172 0.3×	67	4.6k
J H Korn United States	19	617 0.6×	823 0.9×	297 0.4×	320 0.5×	135 0.2×	37	2.1k
Zhi Liu United States	32	2.4k 2.4×	684 0.8×	231 0.3×	199 0.3×	2.0k 3.2×	88	3.9k
Kanako Kikuchi Japan	34	1.6k 1.5×	550 0.6×	385 0.5×	730 1.1×	115 0.2×	106	3.8k
Helena Autio‐Harmainen Finland	39	288 0.3×	392 0.4×	810 1.0×	129 0.2×	291 0.5×	119	4.3k
Atsuyuki Igarashi Japan	31	1.1k 1.1×	1.4k 1.5×	218 0.3×	1.6k 2.4×	151 0.2×	89	4.7k
Émilie Mamessier France	34	397 0.4×	1.8k 2.0×	2.3k 2.8×	148 0.2×	216 0.4×	83	4.3k
Doru T Alexandrescu United States	25	241 0.2×	264 0.3×	567 0.7×	420 0.6×	309 0.5×	77	1.7k
Francesca Cianfarani Italy	20	235 0.2×	814 0.9×	415 0.5×	407 0.6×	215 0.3×	34	2.4k
Constantin A Dasanu United States	26	365 0.4×	371 0.4×	873 1.1×	235 0.3×	467 0.8×	208	2.4k

Countries citing papers authored by Steen Lisby

Since Specialization

Citations

This map shows the geographic impact of Steen Lisby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steen Lisby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steen Lisby more than expected).

Fields of papers citing papers by Steen Lisby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steen Lisby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steen Lisby. The network helps show where Steen Lisby may publish in the future.

Co-authorship network of co-authors of Steen Lisby

This figure shows the co-authorship network connecting the top 25 collaborators of Steen Lisby. A scholar is included among the top collaborators of Steen Lisby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steen Lisby. Steen Lisby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Morgenstern, Daniel A., Jaume Mora, Gcf Chan, et al.. (2020). 74P Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB). Annals of Oncology. 31. S1448–S1448. 5 indexed citations

2.

Chénard-Poirier, Maxime, David S. Hong, Robert L. Coleman, et al.. (2017). A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors. Annals of Oncology. 28. v420–v420. 3 indexed citations

3.

Chénard-Poirier, Maxime, David S. Hong, Robert L. Coleman, et al.. (2017). A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors. Annals of Oncology. 28. v408–v408. 8 indexed citations

4.

Vergote, Ignace, Emma Dean, Ulrik Lassen, et al.. (2017). A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. Annals of Oncology. 28. v330–v331. 6 indexed citations

5.

Österborg, Anders, Andrey Zaritskey, Sebastian Grosicki, et al.. (2016). Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 57(9). 2037–2046. 20 indexed citations

6.

Robak, Tadeusz, Sebastian Grosicki, Krzysztof Warzocha, et al.. (2015). Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2. Haematologica. 100. 3 indexed citations

7.

Oers, Marinus H. J. van, Kazimierz Kuliczkowski, Lukáš Smolej, et al.. (2015). Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology. 16(13). 1370–1379. 84 indexed citations

8.

Matasar, Matthew J., Myron S. Czuczman, Maria Alma Rodriguez, et al.. (2013). Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 122(4). 499–506. 45 indexed citations

9.

Hillmen, Peter, Tadeusz Robak, Ann Janssens, et al.. (2013). Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). Blood. 122(21). 528–528. 58 indexed citations

10.

Machiels, Jean-Pascal, Ágnes Ruzsa, Gábor Répássy, et al.. (2011). Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. The Lancet Oncology. 12(4). 333–343. 163 indexed citations

11.

Lisby, Steen, Annesofie Faurschou, & Robert Gniadecki. (2006). The autocrine TNFα signalling loop in keratinocytes requires atypical PKC species and NF-κB activation but is independent of cholesterol-enriched membrane microdomains. Biochemical Pharmacology. 73(4). 526–533. 17 indexed citations

12.

Lisby, Steen, Robert Gniadecki, & Hans Christian Wulf. (2005). UV‐induced DNA damage in human keratinocytes: Quantitation and correlation with long‐term survival. Experimental Dermatology. 14(5). 349–355. 47 indexed citations

13.

Lisby, Steen, et al.. (2004). Characterization of lymphocyte subpopulations and cytokine profiles in peripheral blood of nickel‐sensitive individuals with systemic contact dermatitis after oral nickel exposure. Contact Dermatitis. 50(1). 31–38. 41 indexed citations

14.

Jensen, Christian S., Torkil Menné, Steen Lisby, Jesper Kristiansen, & Niels K. Veien. (2003). Experimental systemic contact dermatitis from nickel: a dose–response study. Contact Dermatitis. 49(3). 124–132. 84 indexed citations

15.

Lisby, Steen & Carl J. Hauser. (2002). Transcriptional regulation of tumor necrosis factor‐α in keratinocytes mediated by interleukin‐1β and tumor necrosis factor‐α. Experimental Dermatology. 11(6). 592–598. 27 indexed citations

16.

Lisby, Steen, Lars Hestbjerg Hansen, Lone Skov, Torkil Menné, & O Baadsgaard. (1999). Nickel-induced activation of T cells in individuals with negative patch test to nickel sulphate. Archives of Dermatological Research. 291(5). 247–252. 26 indexed citations

17.

Baadsgaard, Ole, et al.. (1990). Gutaneous T-cell lymphoma lesional epidermal cells activate autologous CD4+ T lymphocytes: Involvement of both CDI+OKM5+ and CD1+OKM5-antigen-presenting cells. Journal of Investigative Dermatology. 94(4). 485–491. 1 indexed citations

18.

Vardy, Daniel, et al.. (1990). The Cellular Immune Response to Human Papillomavirus Infection. International Journal of Dermatology. 29(9). 603–610. 20 indexed citations

19.

Wantzin, Gunhild Lange, Elisabeth Ralfkiær, Steen Lisby, & Robert Rothlein. (1988). The role of intercellular adhesion molecules in inflammatory skin reactions. British Journal of Dermatology. 119(2). 141–145. 35 indexed citations

20.

Lisby, Gorm, et al.. (1988). Retroviruses in Dermatology. International Journal of Dermatology. 27(7). 463–467. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact